Displaying 781 - 800 of 1043 results

Chủ Đề Sức Khỏe Về Viêm Khớp Dạng Thấp (Rheumatoid Arthritis)

https://www.niams.nih.gov/es/informacion-de-salud/artritis-reumatoide

Bệnh thấp khớp là bệnh gây ảnh hưởng đến các khớp xương. Bệnh này gây đau, sưng và cứng khớp. Nếu một đầu gối hoặc bàn tay bị thấp khớp, thông thường đầu gối hoặc bàn tay còn lại cũng bị bệnh. Bệnh này thường xảy ra ở nhiều khớp và có thể ảnh hưởng đến bấ

NIAMS Appeals Process

https://www.niams.nih.gov/es/node/7611

NIH has a formal process to resolve disagreements between applicants and NIH review committees and/or NIH staff concerning the referral (assignment) and review of applications. Although procedural aspects of technical merit review are subject to appeal, differences in scientific opinion, such as may occur between applicants and reviewers, may not

FY 2020 Funding Plan

https://www.niams.nih.gov/es/node/7831

Updated August 4, 2020 NIAMS FY 2020 Enacted Level: $624,889,000 The NIAMS is operating under the FY 2020 Further Consolidated Appropriations Act. The interim funding plan below for research and training grants represents the most current information as of the date cited above; however, many factors including a quarterly apportionment

Mechanism Table Fiscal Year 2018

https://www.niams.nih.gov/es/node/7921

October 28, 2019 Fiscal Year 2018 Actual Obligations Budget Mechanism No. of Awards Amount Research Grants Research Project Grants (RPG): Noncompeting 739 $280,157,984 Administrative Supplements (39) 3,071,821 Competing 266 95,968,967 Subtotal 1,005 379,198,772 Small Business Innovation/Technology 47 17,852,612 Subtotal, RPGs 1,052 397,051,384 Research Centers 39 40,922,076 Other Research: Career Programs

Naoko Mizuno, Ph.D.

https://www.niams.nih.gov/es/node/12016

Dr. Mizuno leads the Laboratory of Structural Cell Biology, jointly appointed to NHLBI and NIAMS. She studies the molecular mechanisms governing specialized cell shapes, such as neurons, platelets or activated immune cells, and specific cancer cells.

FY 2023 Congressional Justification

https://www.niams.nih.gov/es/node/12046

The FY2023 NIAMS Congressional Justification is the annual presentation to Congress that justifies the entire NIAMS budget request and reflects the continuing mission to support research into the causes, treatment, and prevention of arthritis and musculoskeletal and skin diseases; the training of basic and clinical scientists to carry out this research; and the dissemination of information on research progress in these diseases.

From the Deputy Director: Piecing Together the Autoimmune Disease Puzzle

https://www.niams.nih.gov/es/node/12051

In her December 2021 letter, NIAMS Director Dr. Lindsey Criswell discussed the launch of the Accelerating Medicines Partnership® Autoimmune and Immune-Mediated Diseases (AMP® AIM) program. This new initiative builds upon the progress of the prior AMP RA/SLE project, which greatly advanced our understanding of the mechanisms that drive disease in rheumatoid arthritis (RA) and lupus.

Typically materials from NIAMS that are more than 5 years old will be archived.